161 related articles for article (PubMed ID: 36346345)
21. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.
Perrin-Terrin A; Pathak A; Lapeyre-Mestre M
Fundam Clin Pharmacol; 2011 Aug; 25(4):503-10. PubMed ID: 20825488
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance and management of drug-related QT interval prolongation.
Crouch MA; Limon L; Cassano AT
Pharmacotherapy; 2003 Jul; 23(7):881-908. PubMed ID: 12885102
[TBL] [Abstract][Full Text] [Related]
23. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients.
Fan W; Liu H; Shen Y; Hong K
Cardiovasc Drugs Ther; 2024 Jun; 38(3):517-525. PubMed ID: 36625987
[TBL] [Abstract][Full Text] [Related]
24. First generation antipsychotic-associated serious adverse events in women: a retrospective analysis of a pharmacovigilance database.
McCall KL; Doughty BJ; Piper BJ; Naik H; Bange S; Leppien EE
Int J Clin Pharm; 2024 Apr; 46(2):515-521. PubMed ID: 38315306
[TBL] [Abstract][Full Text] [Related]
25. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
26. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
27. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation.
Gilmour RF; Riccio ML; Locati EH; Maison-Blanche P; Coumel P; Schwartz PJ
J Am Coll Cardiol; 1997 Jul; 30(1):209-17. PubMed ID: 9207644
[TBL] [Abstract][Full Text] [Related]
28. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
Li D; Chai S; Wang H; Dong J; Qin C; Du D; Wang Y; Du Q; Liu S
Front Pharmacol; 2023; 14():1259611. PubMed ID: 38186652
[No Abstract] [Full Text] [Related]
29. Drug-Induced QT Prolongation and Torsade de Pointes in Spontaneous Adverse Event Reporting: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database (2004-2021).
Uchikawa M; Hashiguchi M; Shiga T
Drugs Real World Outcomes; 2022 Dec; 9(4):551-559. PubMed ID: 35994235
[TBL] [Abstract][Full Text] [Related]
30. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study.
Salem JE; Bretagne M; Lebrun-Vignes B; Waintraub X; Gandjbakhch E; Hidden-Lucet F; Gougis P; Bachelot A; Funck-Brentano C;
Arch Cardiovasc Dis; 2019 Nov; 112(11):699-712. PubMed ID: 31477476
[TBL] [Abstract][Full Text] [Related]
31. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.
Halkin A; Roth A; Lurie I; Fish R; Belhassen B; Viskin S
J Am Coll Cardiol; 2001 Oct; 38(4):1168-74. PubMed ID: 11583899
[TBL] [Abstract][Full Text] [Related]
32. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.
Uvelin A; Pejaković J; Mijatović V
J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241
[TBL] [Abstract][Full Text] [Related]
33. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
34. Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC.
Waliany S; Zhu H; Wakelee H; Padda SK; Das M; Ramchandran K; Myall NJ; Chen T; Witteles RM; Neal JW
J Thorac Oncol; 2021 Dec; 16(12):2029-2039. PubMed ID: 34418561
[TBL] [Abstract][Full Text] [Related]
35. An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.
Luo M; Wu B; Li Y; Wu F
Int J Clin Pharm; 2022 Oct; 44(5):1179-1187. PubMed ID: 35857159
[TBL] [Abstract][Full Text] [Related]
36. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C
Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480
[TBL] [Abstract][Full Text] [Related]
37. Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient.
Ünal Yüksekgönül A; Ertuğrul İ; Karagöz T
Cardiol Young; 2021 Dec; 31(12):2035-2037. PubMed ID: 34024302
[TBL] [Abstract][Full Text] [Related]
38. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).
Anand K; Ensor J; Trachtenberg B; Bernicker EH
JACC CardioOncol; 2019 Dec; 1(2):172-178. PubMed ID: 34396179
[TBL] [Abstract][Full Text] [Related]
39. Protease inhibitor-associated QT interval prolongation.
Hunt K; Hughes CA; Hills-Nieminen C
Ann Pharmacother; 2011 Dec; 45(12):1544-50. PubMed ID: 22128044
[TBL] [Abstract][Full Text] [Related]
40. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
Othong R; Devlin JJ; Kazzi ZN
Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
